HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gammon, D. C. Articles by Glantz, M. J. Search for Related Content PubMed PubMed Citation Articles by Gammon, D. C. Articles by Glantz, M. J.

DAVID C. GAMMON, B.S.PHARM., is Clinical Oncology Pharmacist, Department of Pharmacy, UMass Memorial Medical Center (UMMC), University Campus (UC), Worcester, MA. MANSIS. BHATT, B.S.PHARM., is Clinical Oncology Pharmacist, Department of Pharmacy, UMMC, UC. LAN TRANis a Pharm.D. degree candidate, Massachusetts College of Pharmacy and Health Sciences, Worcester. ALEXIS VAN HORN, R.N., is Neuro-Oncology Nurse, Department of Oncology, UMMC, UC. MATTHEW BENVENUTI, PHARM.D., is Pharmacist, Department of Pharmacy, UMMC, UC. MICHAEL J. GLANTZ, M.D., is Neuro-Oncologist, Department of Oncology, UMMC, UC.

Address correspondence to Mr. Gammon at the Department of Pharmacy, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655 (gammond{at}ummhc.org).

Purpose. The efficacy and safety of intrathecal topotecan were assessed in patients with neoplastic meningitis (NM) by retrospective chart review. Summary. Fourteen patients (median age, 57 years) with NM were treated with the standard of care (i.e., regional or systemic chemotherapy or irradiation or both) plus intrathecal topotecan between January 2004 and September 2005. Three patients developed NM in the setting of systemic cancer; 11 patients had primary central nervous system (CNS) malignancies. All patients received 0.4 mg of topotecan intrathecally two times per week. The efficacy of intrathecal topotecan was assessed on the basis of the number of doses to cerebrospinal fluid (CSF) cytologic clearing—defined as the disappearance of malignant cells from a previously positive CSF cytology. Safety was evaluated by chart documentation of adverse events that might have been associated with topotecan given intrathecally. Of the 11 patients with primary CNS tumors, 6 patients achieved CSF clearing after the first dose of intrathecal topotecan, 2 patients after the second dose, and 1 patient after the fifth dose. For the 3 patients with secondary CSF tumors, 1 patient achieved CSF clearing after the third dose and 2 patients did not reach the primary endpoint. Overall, 6 of the 14 patients achieved CSF clearing after the first dose of intrathecal topotecan; in 10 of the 14 patients, CSF clearing of malignant cells was observed at some point during treatment. Toxicity was modest. The most common adverse effect reported was fatigue. Conclusion. Intrathecal topotecan appeared to be effective and safe in adult patients with NM. Index terms: Antineoplastic agents; Drug administration routes; Meningeal neoplasms; Topotecan; Toxicity